Journal articleiScience · August 21, 2026
Despite advances in treatment approaches, the mean survival for patients with brain metastases remains poor. The incidence of brain metastases continues to rise, and there remains a need to identify novel therapeutics targeting mechanisms critical for brai ...
Full textLink to itemCite
Journal articleNeuro Oncol · August 1, 2026
BACKGROUND: Brain metastases in patients with breast cancer (BCBM) are common. While the Breast Graded Prognostic Assessment (Breast GPA) predicts overall survival (OS), its ability to predict intracranial progression-free survival (icPFS) has not been est ...
Full textLink to itemCite
Journal articleBreast · August 2026
BACKGROUND: Recent years have seen rapid advances in human epidermal growth factor receptor 2 (HER2)-directed therapies for breast cancer. The shifting therapeutic landscape has presented patients and clinicians with a plethora of effective treatment optio ...
Full textLink to itemCite
Journal articleJournal of Clinical Oncology · June 1, 2026
1012Background: T-DXd is approved for adult pts with HER2+ mBC who received a prior anti-HER2–based regimen, or as 1L therapy when given in combination with pertuzumab (P). DESTINY-Breast07 (NCT04538742) is a Phase 1b/2, open-label, platform study explorin ...
Full textCite
Journal articleClin Cancer Res · March 16, 2026
PURPOSE: Establish the safety, tolerability, and preliminary activity of trastuzumab deruxtecan (T-DXd) in combination with other anticancer therapies in human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). PATIENTS AND METHO ...
Full textLink to itemCite
Journal articleNPJ Precis Oncol · March 13, 2026
Trastuzumab deruxtecan (T-DXd) is commonly used for treating metastatic breast cancer (MBC); however, traditional HER2 immunohistochemistry has largely failed to predict T-DXd activity. We reviewed survival outcomes and tested the reliability of multiple H ...
Full textLink to itemCite
Journal articleNeuro Oncol · February 1, 2026
Intracranial metastases (ICM), specifically parenchymal brain metastases, remain a major clinical challenge in solid tumor oncology, despite recent advances in cancer therapies which have led to improvements in survival for these patients. Improving outcom ...
Full textLink to itemCite
Journal articleTrends Cancer · February 2026
Brain metastasis (BrM) represents the most common intracranial malignancy, arising in up to 30% of all adult cancer patients and contributing significantly to cancer-related morbidity and mortality. BrM is now recognized as a biologically distinct conditio ...
Full textLink to itemCite
Journal articleNPJ Breast Cancer · December 20, 2025
Despite improvements in surgical techniques, advances in delivery of radiation therapy, and development of therapies with central nervous system (CNS) activity, the presence of CNS metastases from breast cancer is frequently associated with a poor prognosi ...
Full textLink to itemCite
Journal articleBreast Cancer Res Treat · December 2025
PURPOSE: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), inc ...
Full textLink to itemCite
Journal articleJ Neurooncol · October 2025
PURPOSE: Immunotherapy and stereotactic radiosurgery (SRS) are frequently combined in the management of brain metastases from non-small cell lung cancer (NSCLC) and melanoma. However, concurrent SRS and dual immune-checkpoint inhibition (ICPI) elevate the ...
Full textOpen AccessLink to itemCite
Journal articleInt J Clin Oncol · October 2025
PURPOSE: To describe real-world characteristics and clinical outcomes among patients with HER2+ MBC receiving tucatinib-based treatments. METHODS: This retrospective study included patients diagnosed with HER2+ MBC between January 2017 and December 2022 fr ...
Full textLink to itemCite
Journal articleCancer Epidemiol Biomarkers Prev · September 2, 2025
BACKGROUND: Development of new melanoma therapies has increased survival, and more patients are living to develop brain metastasis (BrM). Identifying those at increased risk of BrM is of significant public health importance, and our objective was to assess ...
Full textLink to itemCite
Journal articleInt J Cancer · August 1, 2025
Lower birth rates and higher pregnancy loss are observed after childhood cancer. Studies specific to adolescent and young adult (AYA) cancer rarely have information on pregnancies that do not end in live birth, fertility preservation strategies, or detaile ...
Full textLink to itemCite
Journal articleActa Neuropathol Commun · June 2, 2025
BACKGROUND: Melanoma brain metastases (MBM) have a unique molecular profile compared to extracranial metastases (ECM). Description of the biological features and clinical outcomes of MBM will facilitate the design of rational therapies. METHODS: We examine ...
Full textLink to itemCite
Journal articleActa Neuropathol Commun · May 12, 2025
BACKGROUND: Brain metastases (BrM) arising from breast cancer (BC) are an increasing consequence of advanced disease, with up to half of patients with metastatic HER2 + or triple negative BC experiencing central nervous system (CNS) recurrence. The genomic ...
Full textLink to itemCite
Journal articleCancer · April 15, 2025
BACKGROUND: Fertility preservation counseling is recommended for reproductive-age cancer patients. Gestational carriers are individuals who carry a pregnancy for someone else. This service creates a path to biological children when cancer treatment necessi ...
Full textLink to itemCite
Journal articleClin Breast Cancer · January 2025
BACKGROUND: It is unclear whether breast cancer (BC) subtypes or CSF cytology results are associated with overall survival (OS) among patients with BC leptomeningeal disease (LMD). This single-institution retrospective study compares OS among BC patients w ...
Full textLink to itemCite
Journal articleESMO Open · January 2025
BACKGROUND: Brain metastases (BMs) are common in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, increasing morbidity and mortality. Systemic therapy for BMs can be effective, with the triple combination of trastuzumab, cap ...
Full textLink to itemCite
Journal articleCancer Control · 2025
Introduction: Tucatinib is an oral human epidermal growth factor receptor 2 (HER2)-targeted therapy approved by the European Medicines Agency (EMA) for use in combination with trastuzumab and capecitabine for patients with HER2 + locally advanced or metast ...
Full textLink to itemCite
Journal articleNeurooncol Adv · 2025
Brain metastases (BrM) arising from solid tumors is an ever-increasing and often devastating clinical challenge impacting hundreds of thousands of patients annually worldwide. As systemic anticancer therapies, and thus survival, improve, the risk for centr ...
Full textLink to itemCite
Journal articleNeurooncol Adv · 2025
BACKGROUND: The impact of systemic therapy (ST) on outcomes for patients with brain-only metastases (BrM) in the absence of extracranial disease (ECD) is not well established. We compared outcomes between patients with BrM treated with stereotactic radiosu ...
Full textLink to itemCite
Journal articleJournal of Clinical Oncology · January 1, 2025
Background: Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple negative breast cancer (mTNBC) and hormone re ...
Full textCite
Journal articleClin Breast Cancer · December 2024
BACKGROUND: Alpelisib is an oral α-specific class I PI3K inhibitor approved in combination with fulvestrant for the treatment of PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast can ...
Full textLink to itemCite
Journal articleNat Med · December 2024
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (mBC) and stable or active (untreated/previous ...
Full textLink to itemCite
Journal articleEur J Cancer · September 2024
With improved systemic treatment and prolonged survival even with metastatic disease, diagnosing, treating, and monitoring brain metastases has become a central topic in the care of patients with melanoma. Patients with brain metastases from melanoma are t ...
Full textLink to itemCite
Journal articleNPJ Breast Cancer · August 2, 2024
The objective of the study is to assess impact of systemic disease (SD) status on overall survival and brain metastasis (BM) control, adopting a novel landmark approach to categorize SD among breast cancer (BC) patients. This single institution retrospecti ...
Full textLink to itemCite
Journal articleClin Cancer Res · April 1, 2024
PURPOSE: We explored the efficacy of PARP inhibition with or without programmed death ligand-1 (PD-L1) blockade as chemotherapy-free maintenance therapy for advanced triple-negative breast cancer (aTNBC) sensitive to platinum-based chemotherapy. PATIENTS A ...
Full textLink to itemCite
Journal articleNeurooncol Adv · 2024
BACKGROUND: Although serum circulating tumor DNA (ctDNA) is routine, data from patients with brain metastases (BrMs) is limited. We assessed genomic alterations in ctDNA from patients with solid tumor BrMs in 3 groups: Isolated BrMs with stable extracrania ...
Full textLink to itemCite
Journal articleJournal of Clinical Oncology · January 1, 2024
Background: Trastuzumab deruxtecan (T-DXd) is approved for adult patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) who received a prior anti-HER2–based regimen. DESTINY-Breast07 is a Phase 1b/2 multicenter, open-label, modular study explori ...
Full textCite
Journal articleJournal of Clinical Oncology · January 1, 2024
Background: Leptomeningeal disease (LMD) in metastatic breast cancer (MBC) carries a poor prognosis. Data on the effect of BC sub types and CSF cytology results on overall survival (OS) are lacking. This single institution retrospective study compares OS a ...
Full textCite
Journal articleClin Breast Cancer · December 2023
The treatment of metastatic breast cancer (MBC) has improved over the past decade, however prognosis continues to be mitigated by the fact that about 1 in 5 patients with MBC will develop brain metastases (BrM) during their metastatic disease course. 1 Thi ...
Full textLink to itemCite
Journal articleLancet Oncol · August 2023
Brain metastases are an increasing global public health concern, even as survival rates improve for patients with metastatic disease. Both metastases and the sequelae of their treatment are key determinants of the inter-related priorities of patient surviv ...
Full textLink to itemCite
Journal articleJ Immunol · July 15, 2023
Previous work from our group and others has shown that patients with breast cancer can generate a T cell response against specific human epidermal growth factor 2 (HER2) epitopes. In addition, preclinical work has shown that this T cell response can be aug ...
Full textLink to itemCite
Journal articleCurr Treat Options Oncol · June 2023
In 2023, breast cancer brain metastases (BCBrM) remain a major clinical challenge gaining well-deserved attention. Historically managed with local therapies alone, systemic therapies including small molecule inhibitors and antibody-drug conjugates (ADCs) h ...
Full textLink to itemCite
Journal articleClin Cancer Res · May 1, 2023
For three years, COVID-19 has circulated among our communities and around the world, fundamentally changing social interactions, health care systems, and service delivery. For people living with (and receiving treatment for) cancer, pandemic conditions pre ...
Full textOpen AccessLink to itemCite
Journal articleBreast Cancer Res Treat · May 2023
PURPOSE: Tumor-infiltrating lymphocytes (TILs) have been positively correlated with response to systemic therapy for triple-negative and HER2 + subtypes and improved clinical outcomes in early breast cancer (BC). Less is known about TILs in metastatic site ...
Full textLink to itemCite
Journal articleClin Cancer Res · April 14, 2023
PURPOSE: Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis. We present results of a phase I trial combining T-DM1 with TMZ for the prevention of additional brain metastases after p ...
Full textLink to itemCite
Journal articleLancet Oncol · April 2023
Successful drug development for people with cancers of the CNS has been challenging. There are multiple barriers to successful drug development including biological factors, rarity of the disease, and ineffective use of clinical trials. Based upon a series ...
Full textLink to itemCite
Journal articleNPJ Breast Cancer · March 30, 2023
Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinic ...
Full textLink to itemCite
Journal articleJAMA Oncol · February 1, 2023
IMPORTANCE: It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor prognosis. Previous reports of the HER2CLIMB trial have demonstrated that tu ...
Full textLink to itemCite
Journal articleLancet Oncol · February 2023
BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in germline BRCA1 or BRCA2 (BRCA1/2) mutation-associated metastatic breast cancer. However, studies evaluating PARP inhibitors plus platinum-based chemotherapy in germline BRCA1/2-wild ...
Full textLink to itemCite
Journal articleClin Cancer Res · January 4, 2023
PURPOSE: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive breast cancer. Because patients with active brain metastases were excluded from previous pivotal clinical trials, the central nervous system (CNS) activity of the an ...
Full textLink to itemCite
Journal articleNat Cancer · January 2023
The AURORA US Metastasis Project was established with the goal to identify molecular features associated with metastasis. We assayed 55 females with metastatic breast cancer (51 primary cancers and 102 metastases) by RNA sequencing, tumor/germline DNA exom ...
Full textLink to itemCite
Journal articleFront Oncol · 2023
BACKGROUND: Tucatinib is an oral human epidermal growth factor receptor 2 (HER2)-directed therapy approved in combination with trastuzumab and capecitabine for use in patients with previously treated HER2+ metastatic breast cancer (MBC) with/without brain ...
Full textLink to itemCite
Journal articleCurr Treat Options Oncol · October 2022
Brain metastasis arising from breast cancer is associated with a poor prognosis. Various systemic chemotherapy and targeted therapies which are effective against breast cancer often fail to provide benefits against brain metastasis. This is mainly due to l ...
Full textLink to itemCite
Journal articleJ Clin Oncol · August 10, 2022
PURPOSE: To update evidence-based guideline recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. METHODS: An Expert Panel conducted a tar ...
Full textLink to itemCite
Journal articleJ Clin Oncol · August 10, 2022
PURPOSE: To provide updated evidence- and consensus-based guideline recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer ...
Full textLink to itemCite
Journal articleJAMA Oncol · July 1, 2022
IMPORTANCE: Patients with breast cancer and brain metastases (BM) have a poor prognosis and high clinical need for novel treatments; however, historically, studies have often excluded these patients. Although the BEACON study did not meet its primary end p ...
Full textLink to itemCite
Journal articleClin Adv Hematol Oncol · May 2022
Up to half of all patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer will eventually acquire brain metastases (BrMs), which are associated with reduced overall survival and decreased quality of life. Although t ...
Link to itemCite
Journal articleCancer Rep (Hoboken) · April 2022
BACKGROUND: Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous system (CN ...
Full textLink to itemCite
Journal articleJ Immunother Cancer · February 2022
PURPOSE: Triple negative breast cancer (TNBC) is characterized by the presence of immune cells in the tumor microenvironment, however, the response to single-agent immune checkpoint inhibitor (ICI) therapy is modest. Preclinical models have demonstrated th ...
Full textLink to itemCite
Journal articleFront Oncol · 2022
BACKGROUND: There is a concern that HER2-directed systemic therapies, when administered concurrently with stereotactic radiosurgery (SRS), may increase the risk of radiation necrosis (RN). This study explores the impact of timing and type of systemic thera ...
Full textLink to itemCite
Journal articleFront Oncol · 2022
BACKGROUND: Triple negative breast cancer (TNBC) is an aggressive variant of breast cancer that lacks the expression of estrogen and progesterone receptors (ER and PR) and HER2. Nearly 50% of patients with advanced TNBC will develop brain metastases (BrM), ...
Full textLink to itemCite
Journal articleMol Cancer Ther · November 2021
Converting human fibroblasts into personalized induced neural stem cells (hiNSC) that actively seek out tumors and deliver cytotoxic agents is a promising approach for treating cancer. Herein, we provide the first evidence that intravenously-infused hiNSCs ...
Full textLink to itemCite
Journal articleNeurooncol Adv · November 2021
The development of breast cancer (BC) brain metastases (BrM) is a common complication of advanced disease, occurring in up to half of the patients with advanced disease depending on the subtype. The management of BCBrM requires complex multidisciplinary ca ...
Full textLink to itemCite
Journal articleNeurooncol Pract · August 2021
INTRODUCTION: Given the high symptom burden and complex clinical decision making associated with a diagnosis of brain metastases (BM), specialty palliative care (PC) can meaningfully improve patient quality of life. However, no prior study has formally eva ...
Full textLink to itemCite
Journal articleNeuro-oncology advances · August 2021
Abstract Background MBM have a unique molecular profile compared to ECM. Methods We analyzed a previously published dataset from MD Anderson Cancer Center, including RNA-seq on surgically resected, FFPE MBM and ECM from the same patients. ...
Cite
Journal articleNeuro-oncology advances · August 2021
Abstract Background In patients with isolated HER2+ BrCBM and no extracranial disease (ECD), there are no consensus guidelines on optimal treatment approaches following CNS-directed therapy. Our goal was to determine the implications of ECD at tim ...
Cite
Journal articleSci Adv · June 2021
Engineered tumor-homing neural stem cells (NSCs) have shown promise in treating cancer. Recently, we transdifferentiated skin fibroblasts into human-induced NSCs (hiNSC) as personalized NSC drug carriers. Here, using a SOX2 and spheroidal culture-based rep ...
Full textLink to itemCite
Journal articleJNCI Cancer Spectr · June 2021
BACKGROUND: Obesity and inactivity are associated with increased risk of cancer-related and overall mortality in breast cancer, but there are few data in metastatic disease. METHODS: Cancer and Leukemia Group B 40502 was a randomized trial of first-line ta ...
Full textLink to itemCite
Journal articleCurr Treat Options Oncol · March 20, 2021
Immune checkpoint blockade (ICB) has revolutionized the treatment landscape across multiple solid tumor types. In triple-negative breast cancer (TNBC), clinical benefit for the addition of ICB to chemotherapy has been shown in both the metastatic and early ...
Full textLink to itemCite
Journal articleMol Cancer Ther · March 2021
Paget's "seed and soil" hypothesis of metastatic spread has acted as a foundation of the field for over a century, with continued evolution as mechanisms of the process have been elucidated. The central nervous system (CNS) presents a unique soil through t ...
Full textLink to itemCite
Journal articleBreast Cancer Res Treat · February 2021
PURPOSE: Metastatic breast cancer (mBC) remains incurable and is associated with low survival rates. This study assessed the efficacy and safety of liposomal irinotecan in heavily pretreated patients with mBC, with or without active brain metastases (BM). ...
Full textLink to itemCite
Journal articleAME Case Rep · 2021
Pancreatic adenocarcinoma commonly presents as metastatic disease and harbors a dire prognosis due to its aggressive behavior, propensity for resistance to therapies, and lack of targetable driver mutations. Additionally, despite advances in other cancers, ...
Full textLink to itemCite
Journal articleAdv Radiat Oncol · 2021
PURPOSE: To examine the effectiveness and safety of single-isocenter multitarget stereotactic radiosurgery using a volume-adapted dosing strategy in patients with 4 to 10 brain metastases. METHODS AND MATERIALS: Adult patients with 4 to 10 brain metastases ...
Full textLink to itemCite
Journal articleFront Oncol · 2021
As local disease control improves, the public health impact of brain metastases (BrM) continues to grow. Molecular features are frequently different between primary and metastatic tumors as a result of clonal evolution during neoplasm migration, selective ...
Full textLink to itemCite
Journal articleJNCI Cancer Spectr · December 2020
BACKGROUND: Although chemotherapy saves lives, increasing evidence shows that chemotherapy accelerates aging. We previously demonstrated that mRNA expression of p16INK4a , a biomarker of senescence and molecular aging, increased early and dramatically afte ...
Full textLink to itemCite
Journal articleNeuro-oncology · November 2020
Abstract INTRODUCTION Breast cancer brain metastasis, including leptomeningeal carcinomatosis (LC), remains one of the most lethal CNS diseases. New therapies are urgently needed to treat this highly aggressive disease. Here we used models of both ...
Cite
Journal articleCancer Res · October 15, 2020
Spread of cancer to the brain remains an unmet clinical need in spite of the increasing number of cases among patients with lung, breast cancer, and melanoma most notably. Although research on brain metastasis was considered a minor aspect in the past due ...
Full textLink to itemCite
Journal articleClin Cancer Res · October 15, 2020
PURPOSE: The primary objective was to evaluate intracranial objective response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to hormone receptor-positive (HR+) metastatic breast cancer (MBC). Secondary ...
Full textLink to itemCite
Journal articleAnn Diagn Pathol · October 2020
OBJECTIVE: Dual probe fluorescence in situ hybridization (FISH) assays for determination of human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer provide a ratio of HER2 to chromosome 17. The ratio may be skewed by copy number ...
Full textLink to itemCite
Journal articleJ Clin Oncol · August 10, 2020
PURPOSE: In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe ex ...
Full textLink to itemCite
Journal articleNeuro-oncology advances · August 2020
Abstract Central nervous system (CNS), notably brain, metastases are most prevalent in lung cancer (20–56% of patients), breast cancer (5–20%) and melanoma (7–16%). Lesions occur in both the brain parenchyma and the meninges. To mechanistically understand ...
Cite
Journal articleNeuro-oncology advances · August 2020
Abstract BACKGROUND HER2CLIMB (NCT02614794) primary results have been reported previously (Murthy, NEJM 2019). We report results of exploratory efficacy analyses in pts with brain metastases (BM). METHODS All HER2+ MBC pts enrolled had a ...
Cite
Journal articleNeuro-oncology advances · August 2020
Abstract INTRODUCTION Leptomeningeal carcinomatosis remains one of the most lethal forms of central nervous system metastasis, with a median survival of only 4 months. Effective new therapies are urgently needed to treat this highly aggressive can ...
Cite
Journal articleClin Cancer Res · June 15, 2020
PURPOSE: ANG1005, a novel taxane derivative, consists of three paclitaxel molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via LRP1 transport system. Preclinical ...
Full textLink to itemCite
Journal articleAm Soc Clin Oncol Educ Book · May 2020
Agents with mechanisms novel to breast cancer care have been approved to treat breast cancer. These agents include drugs that target cyclin-dependent kinases, phosphoinositide 3-kinase PI3KCA gene mutations, PARP, checkpoint regulation, and novel antibody- ...
Full textLink to itemCite
Journal articleClin Breast Cancer · April 2020
PURPOSE: This pilot study was performed to test our ability to administer neratinib monotherapy before clinically recommended craniotomy in patients with HER2-positive metastatic breast cancer to the central nervous system, to examine neratinib's central n ...
Full textLink to itemCite
Journal articleCancer · April 1, 2020
Brain metastasis (BM), the most common adult brain tumor, develops in 20% to 40% of patients with late-stage cancer and traditionally are associated with a poor prognosis. The management of patients with BM has become increasingly complex because of new an ...
Full textLink to itemCite
Journal articleN Engl J Med · February 13, 2020
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, ...
Full textLink to itemCite
Journal articleClin Breast Cancer · February 2020
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with backbone endocrine therapy have markedly improved progression-free survival and overall survival over endocrine therapy alone in advanced hormone receptor-positive, HER2-negative (HR+/HER ...
Full textLink to itemCite
Journal articleCurrent Breast Cancer Reports · December 1, 2019
Purpose of Review: The goal of our review is to describe the rationale for immunotherapy in the treatment of breast cancer brain metastases (BCBM), the current landscape of clinical trials for this disease process, and possible future directions based on a ...
Full textCite
Journal articleClin Cancer Res · November 15, 2019
The incidence of brain metastases is increasing as cancer therapies improve and patients live longer, providing new challenges to the multidisciplinary teams that care for these patients. Brain metastatic cancer cells possess unique characteristics that al ...
Full textLink to itemCite
Journal articleNeuro-oncology · November 2019
Abstract INTRODUCTION Non-small cell lung cancer (NSCLC) and breast cancer are the most common cancers that metastasize to the brain. New therapies are needed to target and eradicate metastases. We have developed genetically-engineered induced neu ...
Cite
Journal articleJ Immunother Cancer · October 18, 2019
The interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast cancer lesions remaining largely understudied. To a ...
Full textLink to itemCite
Journal articleCancer · September 1, 2019
BACKGROUND: In the current study, the authors investigated the incidence of moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) for chemotherapy regimens commonly used in current clinical practice for the treatment of patients with early b ...
Full textLink to itemCite
Journal articleNeuro-oncology advances · August 2019
Abstract BACKGROUND: nal-IRI is a liposomal formulation of irinotecan (topoisomerase-1 inhibitor). Preclinical data show that nal-IRI accumulates in BMs and prolongs survival in animal models of BM. Findings from a phase 1 expansion study (NCT01770353), ev ...
Cite
Journal articleNeuro-oncology advances · August 2019
Abstract INTRODUCTION: Approximately 50% of patients with metastatic triple negative breast cancer (TNBC) will develop brain metastases (BM). Routinely treated with radiotherapy and/or surgery, survival is generally less than one year. There are no approve ...
Cite
Journal articleNeuro-oncology advances · August 2019
Abstract INTRODUCTION: Non-small cell lung cancer (NSCLC) and breast cancer are the most common cancers that metastasize to the brain. New therapies are needed to seek out and eradicate metastases. Genetically engineered neural stem cells (NSCs) have shown ...
Cite
Journal articleNeuro-oncology advances · August 2019
Abstract BACKGROUND: Patients with a large number of brain metastases (BM) and/or micrometastatic disease in the brain present a clinical challenge. While technical innovations in stereotactic radiosurgery (SRS) have extended the number of BM that can be e ...
Cite
Journal articleNeuro-oncology advances · August 2019
Abstract Brain metastases are a common consequence of advanced lung and breast cancer resulting in functional impairment, cranial neuropathies, and decline in quality of life. Current therapies for brain metastasis, such as whole brain radiation therapy, c ...
Cite
Journal articleJAMA Oncol · August 1, 2019
IMPORTANCE: Poly(adenosine diphosphate-ribose) polymerase inhibitor and anti-programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in patients with advanced triple-negative breast cancer (TNBC). OBJECTIVE: To evaluate the c ...
Full textLink to itemCite
Journal articleJ Clin Oncol · August 1, 2019
PURPOSE: To update the American Society of Clinical Oncology endorsement of the Cancer Care Ontario recommendations on the Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer. METHODS: Tw ...
Full textLink to itemCite
Journal articleBreast Cancer Res Treat · July 2019
PURPOSE: Brain metastases (BM) are a complication of advanced breast cancer (BC). Histology of melanoma BM offers prognostic value; however, understanding the microenvironment of breast cancer brain metastases (BCBM) is less characterized. This study repor ...
Full textLink to itemCite
Journal articleFuture Oncol · July 2019
The increasing incidence of breast cancer brain metastases is a major clinical problem with its associated poor prognosis and limited treatment options. The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed to preferentially accumulat ...
Full textLink to itemCite
Journal articleOncologist · June 2019
BACKGROUND: This study explores the incidence of patient-reported major toxicity-symptoms rated "moderate," "severe," or "very severe"-for chemotherapy regimens commonly used in early breast cancer. PATIENTS AND METHODS: Female patients aged 21 years or ol ...
Full textLink to itemCite
Journal articleJ Clin Oncol · May 1, 2019
PURPOSE: Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastas ...
Full textLink to itemCite
Journal articleNat Rev Dis Primers · January 17, 2019
An estimated 20% of all patients with cancer will develop brain metastases, with the majority of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma or renal cell carcinoma. Brain metastases are thought to occur via seedi ...
Full textLink to itemCite
Journal articleNeurooncol Adv · 2019
BACKGROUND: Despite the poor prognosis of triple-negative breast cancer (TNBC) brain metastases, there are no approved systemic therapies. We explored the DNA-damaging poly(ADP-ribose) polymerase inhibitor (PARPi) niraparib in intracranial mouse models of ...
Full textLink to itemCite
Journal articleBreast Cancer Res Treat · January 2019
In the original publication, the sixth author name was published incorrectly as A. Wood. The correct author name should read as W. A. Wood. ...
Full textLink to itemCite
Journal articlePediatr Blood Cancer · December 2018
Breast cancer is the most common cancer of adolescents and young adult (AYA) women aged 15 to 39 years, accounting for 5.6% of all invasive breast cancer in women. In comparison with older women, AYAs are more likely to have familial cancer predisposition ...
Full textLink to itemCite
Journal articleNpj Breast Cancer · December 1, 2018
Serial monitoring of plasma DNA mutations in estrogen receptor positive metastatic breast cancer (ER + MBC) holds promise as an early predictor of therapeutic response. Here, we developed dPCR-SEQ, a customized assay that utilizes digital PCR-based target ...
Full textCite
Journal articleOncology (Williston Park) · October 15, 2018
Adjuvant human epidermal growth factor receptor 2 (HER2)-directed treatment has changed dramatically over the past decade. Historically, the addition of 1 year of trastuzumab to adjuvant chemotherapy has significantly improved both disease-free survival an ...
Link to itemCite
Journal articleBreast Cancer Res Treat · October 2018
PURPOSE: HER2 + breast cancer (BC) is an aggressive subtype with high rates of brain metastases (BCBM). Two-thirds of HER2 + BCBM demonstrate activation of the PI3K/mTOR pathway driving resistance to anti-HER2 therapy. This phase II study evaluated everoli ...
Full textLink to itemCite
Journal articleClin Breast Cancer · August 2018
BACKGROUND: Buparlisib is an oral pan-class I phosphotidyinositol-3-kinase (PI3K) inhibitor. The present phase I study evaluated the safety, pharmacokinetics, and efficacy of buparlisib with capecitabine in patients with metastatic breast cancer. PATIENTS ...
Full textLink to itemCite
Journal articleInt J Cancer · May 15, 2018
Reproductive outcomes are an important survivorship concern for women diagnosed with cancer as adolescents and young adults (AYAs). We examined the incidence of live birth and the prevalence of adverse birth outcomes according to tumor and treatment charac ...
Full textLink to itemCite
Journal articleAnn Transl Med · May 2018
One of the most feared sequelae after a diagnosis of advanced breast cancer is development of metastases to the brain as this diagnosis can affect physical function, independence, relationships, quality of life, personality, and ultimately one's sense of s ...
Full textLink to itemCite
Journal articleJ Clin Invest · April 2, 2018
Breast cancer metastasis remains a clinical challenge, even within a single patient across multiple sites of the disease. Genome-wide comparisons of both the DNA and gene expression of primary tumors and metastases in multiple patients could help elucidate ...
Full textLink to itemCite
Journal articleBreast Cancer Res Treat · February 2018
PURPOSE: Ensuring and measuring adherence to prescribed exercise regimens are fundamental challenges in intervention studies to promote exercise in adults with cancer. This study reports exercise adherence in women who were asked to walk 150 min/week throu ...
Full textLink to itemCite
Journal articleClin Breast Cancer · February 2018
BACKGROUND: Given the wide adoption of human epidermal growth factor receptor 2 (HER2)-targeted therapies for advanced HER2-positive breast cancer, we studied the natural history of patients with HER2-positive breast cancer brain metastases (BCBM) over tim ...
Full textLink to itemCite
Journal articleCancer Epidemiol Biomarkers Prev · December 2017
Background: African American (AA) women have higher incidence of aggressive, young-onset (<40 years) breast cancers. Young- and older-onset disease may have distinct tumor biologies and etiologies; however, studies investigating age differences among AA wo ...
Full textLink to itemCite
Journal articleCurrent Breast Cancer Reports · December 1, 2017
Purpose of Review: Over 25% of patients with metastatic breast cancer will develop brain metastases. Recent advances in systemic therapy, especially molecularly targeted agents, have improved control of extracranial disease, but have had limited effect on ...
Full textCite
Journal articleNeuro Oncol · October 19, 2017
BACKGROUND: Triple-negative breast cancer (TNBC), lacking expression of hormone and human epidermal growth factor receptor 2 receptors, is an aggressive subtype that frequently metastasizes to the brain and has no FDA-approved systemic therapies. Previous ...
Full textLink to itemCite
Journal articleNeuro Oncol · October 19, 2017
BACKGROUND: Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Prognosis remains poor despite multimodal therapy. Developing alternative treatments is essential. Drugs targeting kinases within the phosphoinositide 3-kinase (PI3K) and ...
Full textLink to itemCite
Journal articleClin Cancer Res · October 1, 2017
Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified metastatic ...
Full textLink to itemCite
Journal articleAm J Pathol · October 2017
Breast cancer represents a heterogeneous collection of diseases with disparate clinical behaviors, responses to treatment, and patient outcomes, despite common histopathological features at diagnosis. Examination of molecular signatures of breast cancer (b ...
Full textLink to itemCite
Journal articleJ Clin Invest · September 1, 2017
Claudin-low breast cancer is an aggressive subtype that confers poor prognosis and is found largely within the clinical triple-negative group of breast cancer patients. Here, we have shown that intrinsic and immune cell gene signatures distinguish the clau ...
Full textLink to itemCite
Journal articleJAMA Oncol · August 1, 2017
IMPORTANCE: Cancer diagnosis and treatment may adversely affect reproductive outcomes among female cancer survivors. OBJECTIVE: To compare the birth outcomes of adolescent and young adult cancer survivors (AYA [diagnosed at ages 15-39 years]) with those of ...
Full textLink to itemCite
Journal articleSci Transl Med · May 24, 2017
Although targeted therapies are often effective systemically, they fail to adequately control brain metastases. In preclinical models of breast cancer that faithfully recapitulate the disparate clinical responses in these microenvironments, we observed tha ...
Full textLink to itemCite
Journal articleClin Breast Cancer · April 2017
OBJECTIVES: Communication between medical oncologists (MOs) and plastic surgeons (PSs) is important to optimize outcomes for patients with breast cancer seeking breast reconstruction. We sought to evaluate the knowledge MOs and PSs have of each others' fie ...
Full textLink to itemCite
Journal articleOncologist · March 2017
BACKGROUND: Although breast cancer during pregnancy (BCDP) is rare (occurring with only 0.4% of all BC diagnoses in female patients aged 16-49 years), management decisions are challenging to both the patient and the multidisciplinary team. MATERIALS AND ME ...
Full textLink to itemCite
Journal articleCancer Causes Control · November 2016
PURPOSE: Endocrine therapy for breast cancer can exacerbate menopausal symptoms. The association between endocrine therapy and common pelvic floor disorders including urinary incontinence has rarely been evaluated. We examined urogenital and sexual side ef ...
Full textLink to itemCite
Journal articleOncology (Williston Park) · October 15, 2016
This review summarizes the most up-to-date approach to the multidisciplinary management of patients with breast cancer brain metastases. A brief overview of the epidemiology and biology of breast cancer brain metastasis is provided. The perspectives of rad ...
Link to itemCite
Journal articleNeuro-oncology · September 2016
Abstract Introduction: Treatment options for brain metastases (BM) and leptomeningeal carcinomatosis (LC) are limited due to the inability of most anti-cancer agents to cross the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier ...
Cite
Journal articleBreast Cancer Res · August 4, 2016
BACKGROUND: Young-onset breast cancer (<40 years) is associated with worse prognosis and higher mortality. Breast cancer risk factors may contribute to distinct tumor biology and distinct age at onset, but understanding of these relationships has been hamp ...
Full textLink to itemCite
Journal articleNanomedicine (Lond) · August 2016
AIM: Particle Replication in Nonwetting Templates (PRINT(®)) PLGA nanoparticles of docetaxel and acid-labile C2-dimethyl-Si-Docetaxel were evaluated with small molecule docetaxel as treatments for non-small-cell lung cancer brain metastases. MATERIALS & ME ...
Full textLink to itemCite
Journal articleNeuro Oncol · August 2016
The clinical management/understanding of brain metastases (BM) has changed substantially in the last 5 years, with key advances and clinical trials highlighted in this review. Several of these changes stem from improvements in systemic therapy, which have ...
Full textLink to itemCite
Journal articleJ Clin Oncol · July 1, 2016
PURPOSE: An American Society of Clinical Oncology (ASCO) panel considered the Cancer Care Ontario (CCO) recommendations on the role of patient and disease factors in selecting adjuvant therapy for women with early-stage breast cancer for endorsement. METHO ...
Full textLink to itemCite
Journal articleCancer · April 1, 2016
Adolescent and young adult (AYA) patients with cancer have not attained the same improvements in overall survival as either younger children or older adults. One possible reason for this disparity may be that the AYA cancers exhibit unique biologic charact ...
Full textLink to itemCite
Journal articleJ Clin Oncol · February 20, 2016
PURPOSE: Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free survival in metastatic disease. CALGB 40601 examined the impact of dual HER2 ...
Full textLink to itemCite
Journal articleAm Soc Clin Oncol Educ Book · 2016
Triple-negative breast cancer (TNBC) is clinically defined as lacking expression of the estrogen receptor (ER), progesterone receptor (ER), and HER2. Historically, TNBC has been characterized by an aggressive natural history and worse disease-specific outc ...
Full textLink to itemCite
Journal articleCancer Treat Commun · 2016
The incidence of breast cancer brain metastasis (BCBM) is increasing due in part to improved management of systemic disease and prolonged survival. Despite this growing population of patients, there exists little consensus for the treatment of HER2-positiv ...
Full textLink to itemCite
Journal articleJ Comput Assist Tomogr · 2016
PURPOSE: Susceptibility-weighted imaging (SWI) has significantly increased our sensitivity in detecting hemorrhagic brain lesions. We sought to explore the prevalence of intratumoral hemorrhage as detected by SWI in brain metastases from melanoma and breas ...
Full textLink to itemCite
Journal articleOncologist · January 2016
BACKGROUND: Breast cancer brain metastasis (BCBM) confers a poor prognosis and is unusual in requiring multidisciplinary care in the metastatic setting. The University of North Carolina at Chapel Hill (UNC-CH) has created a BCBM clinic to provide medical a ...
Full textLink to itemCite
Journal articleOncotarget · May 30, 2015
BACKGROUND: Young women with breast cancer experience inferior outcome and commonly manifest aggressive biological subtypes. Data is controversial regarding biological differences between breast tumors in young (diagnosed at <40 years of age) versus older ...
Full textLink to itemCite
Journal articleMol Cancer Ther · April 2015
Patients with breast cancer brain metastases have extremely limited survival and no approved systemic therapeutics. Triple-negative breast cancer (TNBC) commonly metastasizes to the brain and predicts poor prognosis. TNBC frequently harbors BRCA mutations ...
Full textLink to itemCite
Journal articleBreast Cancer Res Treat · April 2015
The effect of race on breast cancer outcome is confounded by tumor and treatment heterogeneity. We examined a cohort of women with stage II-III breast cancer treated uniformly with neoadjuvant chemotherapy to identify factors associated with racial differe ...
Full textLink to itemCite
Journal articleSci Transl Med · February 4, 2015
Parenteral and oral routes have been the traditional methods of administering cytotoxic agents to cancer patients. Unfortunately, the maximum potential effect of these cytotoxic agents has been limited because of systemic toxicity and poor tumor perfusion. ...
Full textLink to itemCite
Journal articleBreast Cancer Res Treat · January 2015
DNA damage recognition and repair is a complex system of genes focused on maintaining genomic stability. Recently, there has been a focus on how breast cancer susceptibility relates to genetic variation in the DNA bypass polymerases pathway. Race-stratifie ...
Full textLink to itemCite
Journal articleNeuro-oncology · November 2014
BACKGROUND: Without active delivery across the blood-brain barrier, the efficacy of doxorubicin is limited in the treatment of brain tumors. 2B3-101 was developed as a brain-targeted doxorubicin product. In preclinical studies, 2B3-101 showed a 5-fold incr ...
Cite
Journal articleOncologist · October 2014
PURPOSE: Breast cancer (BC) is a disease of aging and the number of older BC patients in the U.S. is rising. Immunohistochemical data show that with increasing age, the incidence of hormone receptor-positive tumors increases, whereas the incidence of tripl ...
Full textLink to itemCite
Journal articleNeuro-oncology · September 2014
BACKGROUND: Without active delivery across the blood-brain barrier (BBB), efficacy of doxorubicin in intracranial tumors is limited. Glutathione pegylated liposomal doxorubicin (2B3-101) was developed as a brain-targeted chemotherapy. In rats treated with ...
Cite
Journal articleBreast Cancer Res Treat · August 2014
Nearly half of patients with advanced triple negative breast cancer (TNBC) develop brain metastases (BM) and most will also have uncontrolled extracranial disease. This study evaluated the safety and efficacy of iniparib, a small molecule anti-cancer agent ...
Full textLink to itemCite
Journal articleBreast Cancer Res · May 6, 2014
Brain metastases remain a significant challenge in the treatment of breast cancer patients due to the unique environment posed by the central nervous system. A better understanding of the biology of breast cancer cells that have metastasized to the brain i ...
Full textLink to itemCite
Journal articleBreast Cancer Research and Treatment · January 1, 2014
Nearly half of patients with advanced triple negative breast cancer (TNBC) develop brain metastases (BM) and most will also have uncontrolled extracranial disease. This study evaluated the safety and efficacy of iniparib, a small molecule anti-cancer agent ...
Full textCite
Journal articleClin Cancer Res · January 1, 2014
PURPOSE: Basal-like breast tumors are typically (ER/PR/HER2) triple-negative and are associated with a high incidence of brain metastases and poor clinical outcomes. The molecular chaperone αB-crystallin is predominantly expressed in triple-negative breast ...
Full textLink to itemCite
Journal articleOncology (Williston Park) · September 2013
Triple-negative breast cancer (TNBC) lacks the three most commonly targeted receptors in human breast cancer--the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)/neu--and it is associated with an aggr ...
Link to itemCite
Journal articleJ Natl Compr Canc Netw · September 1, 2013
Breast cancer is a substantial contributor to adolescent and young adult (AYA) malignancies, defined as a diagnosis of cancer between the ages of 15 and 39. In the United States, 6.6% of breast cancer cases are diagnosed among women younger than 40 years. ...
Full textLink to itemCite
Journal articleHematol Oncol Clin North Am · August 2013
Triple-negative breast cancer (TNBC), defined as lacking expression of the estrogen receptor, progesterone receptor, and HER2, comprises approximately 15% of incident breast cancers and is over-represented among those with metastatic disease. There are sev ...
Full textLink to itemCite
Journal articleOncologist · 2013
Triple-negative (TN) and basal-like (BL) breast cancer definitions have been used interchangeably to identify breast cancers that lack expression of the hormone receptors and overexpression and/or amplification of HER2. However, both classifications show s ...
Full textLink to itemCite
Journal articlePLoS One · 2013
INTRODUCTION: Breast cancer brain metastases (BCBM) are a challenging consequence of advanced BC. Nanoparticle agents, including liposomes, have shown enhanced delivery to solid tumors and brain. We compared pharmacokinetics (PK) and efficacy of PEGylated ...
Full textLink to itemCite
Journal articleBreast Cancer Res Treat · April 2012
The ability to predict metastatic potential could be of great clinical importance, however, it is uncertain if predicting metastasis to specific vital organs is feasible. As a first step in evaluating metastatic predictions, we analyzed multiple primary tu ...
Full textLink to itemCite
Journal articleCurr Breast Cancer Rep · March 1, 2012
Approximately 10% to 15% of women with metastatic breast cancer will develop brain metastases. Treatment options for these women remain limited, particularly at the time of central nervous system (CNS) relapse following completion of initial CNS-directed t ...
Full textLink to itemCite
Journal articleInt J Breast Cancer · 2012
Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality asso ...
Full textLink to itemCite
Journal articlePLoS ONE · December 1, 2011
Background: A major challenge in oncology is the selection of the most effective chemotherapeutic agents for individual patients, while the administration of ineffective chemotherapy increases mortality and decreases quality of life in cancer patients. Thi ...
Full textCite
Journal articleAm Surg · July 2011
Women with locally advanced breast cancer (LABC) who are breast conservation (BCT) candidates after neoadjuvant chemotherapy have the best long-term outcome and low local-regional recurrence (LRR) rates. However, young women are thought to have a higher ri ...
Link to itemCite
Journal articleCancer · April 15, 2011
BACKGROUND: Brain metastases (BM) arising from triple-negative breast cancer (TNBC) portend a poor prognosis. TNBC is more common in premenopausal and African-American (AA) patients; both of these characteristics also confer a poor prognosis. In a single-i ...
Full textLink to itemCite
Journal articleBreast Cancer Res · April 1, 2011
Triple-negative breast cancers (TNBC) have increased rates of pathologic complete response following neoadjuvant chemotherapy, yet have poorer prognosis compared with non-TNBC. Known as the triple-negative paradox, this highlights the need to dissect the b ...
Full textLink to itemCite
Journal articleBreast Cancer Res · 2011
INTRODUCTION: Activation status of the phosphatidylinositol 3-kinase (PI3K) pathway in breast cancer brain metastases (BCBMs) is largely unknown. We examined expression of phospho(p)-AKT, p-S6, and phosphatase and tensin homologue (PTEN) in BCBMs and their ...
Full textLink to itemCite
Journal articleClin Cancer Res · October 1, 2010
In contrast to endocrine-sensitive and human epidermal growth factor receptor 2 (HER2)-positive breast cancer, novel agents capable of treating advanced triple-negative breast cancer (TNBC) are lacking. Poly(ADP-ribose) polymerase (PARP) inhibitors are eme ...
Full textLink to itemCite
Journal articleFertil Steril · October 2010
OBJECTIVE: To survey oncologists regarding their knowledge and practice patterns concerning fertility preservation for female cancer patients. DESIGN: An online survey was sent to oncologists at cancer centers ranked by U.S. News & World Report. SETTING: O ...
Full textLink to itemCite
Journal articleCancer Invest · August 2010
The host immune response can impact cancer growth, prognosis, and response to therapy. In colorectal cancer, the presence of cells involved with T-cell-mediated adaptive immunity predicts survival better than the current staging method. We used the express ...
Full textLink to itemCite
Journal articleClin Breast Cancer · June 2009
Of the estimated 1 million cases of breast cancer diagnosed annually worldwide, it is estimated that over 170,000 will harbor the triple-negative (estrogen receptor/progesterone receptor/HER2-negative) phenotype. Most, though not all, triple-negative breas ...
Full textLink to itemCite
Journal articleSemin Oncol · June 2009
Approximately 7% of women with breast cancer are diagnosed before the age of 40 years, and this disease accounts for more than 40% of all cancer in women in this age group. Survival rates are worse when compared to those in older women, and multivariate an ...
Full textLink to itemCite
Journal articleJ Reprod Med · April 2009
OBJECTIVE: To conduct a quantitative survey that focuses on oncologists' practice patterns and attitudes surrounding treatment-related infertility and fertility preservation, specifically among women of reproductive age. STUDY DESIGN: A 19-item survey was ...
Link to itemCite
Journal articleJ Womens Health (Larchmt) · March 2009
PURPOSE: Treatment with cyclophosphamide (CYC) confers up to a 40% risk of ovarian failure in women of reproductive age. The use of GnRH agonists (GnRHa) to preserve ovarian function has been investigated in several small studies. We performed a systematic ...
Full textLink to itemCite
Journal articleBreast Cancer Res · 2009
INTRODUCTION: Perhaps the major challenge in developing more effective therapeutic strategies for the treatment of breast cancer patients is confronting the heterogeneity of the disease, recognizing that breast cancer is not one disease but multiple disord ...
Full textLink to itemCite
Journal articleOncology (Williston Park) · October 2008
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile, aggressive behavior, distinct patte ...
Link to itemCite
Journal articleJ Clin Oncol · July 10, 2008
PURPOSE: Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined. PATIENTS AND METHODS: Clinically annotated, m ...
Full textLink to itemCite
Journal articleJAMA · April 2, 2008
CONTEXT: Gene expression profiling may be useful for prognostic and therapeutic strategies in breast carcinoma. OBJECTIVES: To demonstrate the value in integrating genomic information with clinical and pathological risk factors, to refine prognosis, and to ...
Full textLink to itemCite
Journal articlePLoS One · April 2, 2008
BACKGROUND: A major challenge in oncology is the selection of the most effective chemotherapeutic agents for individual patients, while the administration of ineffective chemotherapy increases mortality and decreases quality of life in cancer patients. Thi ...
Full textOpen AccessLink to itemCite
Journal articlePLoS One · January 2, 2008
PURPOSE: To define the biology driving the aggressive nature of breast cancer arising in young women. EXPERIMENTAL DESIGN: Among 784 patients with early stage breast cancer, using prospectively-defined, age-specific cohorts (young or=6 ...
Full textOpen AccessLink to itemCite
Journal articleCancer Invest · 2008
BACKGROUND: Premenopausal women treated for early stage breast cancer (ESBC) are at risk for chemotherapy-related amenorrhea (CRA). Prospectively-validated, predictive markers of CRA are needed. PATIENTS AND METHODS: Premenopausal women with ESBC and plann ...
Full textLink to itemCite
Journal articleJ Clin Oncol · October 1, 2007
PURPOSE: Standard treatment for advanced non-small-cell lung cancer (NSCLC) includes the use of a platinum-based chemotherapy regimen. However, response rates are highly variable. Newer agents, such as pemetrexed, have shown significant activity as second- ...
Full textLink to itemCite
Journal articleJ Transl Med · September 6, 2007
BACKGROUND: The HER2-inhibiting antibody trastuzumab, in combination with chemotherapy, significantly improves survival of women with resected, HER2-overexpressing breast cancers, but is associated with toxicities including a risk of cardiomyopathy. Additi ...
Full textLink to itemCite
